Ubiquigent Limited announces that it has launched the first commercially available compound library comprising novel small molecules designed to target deubiquitylase (DUB) enzymes, DUBtarget-001.
To mark the launch of the library Dr John Harris (Ubiquigent Scientific Advisory Board member) will today be presenting DUBtarget™-001 at the Society of Chemical Industry (SCI) conference – Innovation in design, supply and acquisition for compound screening libraries.
Ubiquigent, in collaboration with the Drug Discovery Unit (DDU) at the University of Dundee, have jointly developed the library to support both commercial and academic researchers looking to either enter the ubiquitin drug discovery field or to support those with active programmes but who are seeking access to additional chemical diversity.
The design of DUBtarget-001 (led by Dr Andrew Woodland of the DDU) has been informed by DUB-related structural data to yield a library with the potential to have activity across multiple DUB families. Ubiquigent has already screened the library against USP2 (a DUB with potential roles in oncology) and demonstrated a significant number of hits from different structural classes. These structures represent multiple starting points with the potential to lead to the development of novel therapeutic and tool compounds.
The library is now available in either its physical form for screening within researchers’ own laboratories or as a dataset where the library will be screened against any of the 40 other DUB enzymes included within Ubiquigent’s DUBprofiler screening platform.
